E P Krenning

Summary

Affiliation: Erasmus University Medical Center
Country: The Netherlands

Publications

  1. ncbi request reprint Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
    E P Krenning
    Department of Nuclear Medicine, University Hospital and Erasmus University Rotterdam, The Netherlands
    Ann Oncol 10:S23-9. 1999
  2. ncbi request reprint Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy
    M De Jong
    Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Int J Cancer 75:406-11. 1998
  3. ncbi request reprint Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy
    M De Jong
    Department of Nuclear Medicine, University Hospital, Dijkigt, Rotterdam, The Netherlands
    Cancer Res 58:437-41. 1998
  4. ncbi request reprint [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients
    D J Kwekkeboom
    Department of Nuclear Medicine, University Hospital Rotterdam, The Netherlands
    Eur J Nucl Med 28:1319-25. 2001
  5. ncbi request reprint Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives
    W A Breeman
    Department of Nuclear Medicine, Erasmus Medical Centre Rotterdam, The Netherlands
    Eur J Nucl Med 28:1421-9. 2001
  6. ncbi request reprint Effects of ligand priming and multiple-dose injection on tissue uptake of 111In-pentetreotide in rats
    W A Breeman
    Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Nucl Med Biol 24:749-53. 1997
  7. ncbi request reprint Tissue distribution and metabolism of radioiodinated DTPA0, D-Tyr1 and Tyr3 derivatives of octreotide in rats
    W A Breeman
    Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Anticancer Res 18:83-9. 1998
  8. ncbi request reprint [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy
    M De Jong
    Department of Nuclear Medicine, University Hospital and Erasmus University Rotterdam, 3015 GD Rotterdam, The Netherlands
    Int J Cancer 92:628-33. 2001
  9. ncbi request reprint Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy
    W A Breeman
    Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Int J Cancer 83:657-63. 1999
  10. ncbi request reprint Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size
    M De Jong
    Department of Nuclear Medicine, Erasmus University Rotterdam, Rotterdam, The Netherlands
    J Nucl Med 42:1841-6. 2001

Collaborators

Detail Information

Publications37

  1. ncbi request reprint Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
    E P Krenning
    Department of Nuclear Medicine, University Hospital and Erasmus University Rotterdam, The Netherlands
    Ann Oncol 10:S23-9. 1999
    ..Peptide receptor scintigraphy with the radioactive somatostatin analogue, [111In-DTPA0]octreotide, is a sensitive and specific technique to show in vivo the presence and abundance of somatostatin receptors on various tumours...
  2. ncbi request reprint Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy
    M De Jong
    Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Int J Cancer 75:406-11. 1998
    ..Renal uptake of 111In-labelled [DTPA0]octreotide, [DTPA0,Tyr3]octreotide and [DOTA0,Tyr3]octreotide was reduced over 50% by an i.v. injection of 400 mg/kg D-lysine, whereas radioactivity in blood, pancreas and adrenals was not affected...
  3. ncbi request reprint Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy
    M De Jong
    Department of Nuclear Medicine, University Hospital, Dijkigt, Rotterdam, The Netherlands
    Cancer Res 58:437-41. 1998
    ..In conclusion, radiolabeled [DTPA0,Tyr3]octreotide and, especially, [DTPA0,Tyr3]octreotate and their DOTA-coupled counterparts are most promising for scintigraphy and radionuclide therapy of SS receptor-positive tumors in humans...
  4. ncbi request reprint [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients
    D J Kwekkeboom
    Department of Nuclear Medicine, University Hospital Rotterdam, The Netherlands
    Eur J Nucl Med 28:1319-25. 2001
    ....
  5. ncbi request reprint Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives
    W A Breeman
    Department of Nuclear Medicine, Erasmus Medical Centre Rotterdam, The Netherlands
    Eur J Nucl Med 28:1421-9. 2001
    ..New somatostatin analogues, new chelators, "new" radionuclides and combinations thereof are also discussed. Due attention is given to limitations and future perspectives of somatostatin receptor-mediated imaging and therapy...
  6. ncbi request reprint Effects of ligand priming and multiple-dose injection on tissue uptake of 111In-pentetreotide in rats
    W A Breeman
    Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Nucl Med Biol 24:749-53. 1997
    ..These findings indicate rapid processing of receptor-bound octreotide and suggest that octreotide treatment of patients undergoing 111In-pentetreotide scintigraphy may be reinitiated as soon as 1 h after radioligand administration...
  7. ncbi request reprint Tissue distribution and metabolism of radioiodinated DTPA0, D-Tyr1 and Tyr3 derivatives of octreotide in rats
    W A Breeman
    Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Anticancer Res 18:83-9. 1998
    ....
  8. ncbi request reprint [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy
    M De Jong
    Department of Nuclear Medicine, University Hospital and Erasmus University Rotterdam, 3015 GD Rotterdam, The Netherlands
    Int J Cancer 92:628-33. 2001
    ..This candidate molecule shows great promise for radionuclide therapy in patients with sst(2)-expressing tumors...
  9. ncbi request reprint Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy
    W A Breeman
    Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Int J Cancer 83:657-63. 1999
    ..The CA20948 tumour, inoculated in the hindleg, was also visualized scintigraphically. [(111)In-DTPA-Pro(1), Tyr(4)]BN appears to be a promising radioligand for scintigraphy of BNR-expressing tumours...
  10. ncbi request reprint Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size
    M De Jong
    Department of Nuclear Medicine, Erasmus University Rotterdam, Rotterdam, The Netherlands
    J Nucl Med 42:1841-6. 2001
    ..CONCLUSION: This study shows the ability of [(90)Y-DOTA(0),Tyr(3)]octreotide to control tumor growth, especially in medium-sized tumors. The effect of radionuclide therapy appeared to be dependent on tumor size at the onset of therapy...
  11. ncbi request reprint Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy
    W A Breeman
    Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Int J Cancer 81:658-65. 1999
    ..We conclude that [(111)In-DTPA-Pro1,Tyr4]BN has promising characteristics for applications in nuclear medicine...
  12. pmc Lutetium-labelled peptides for therapy of neuroendocrine tumours
    B L R Kam
    Department of Nuclear Medicine, Erasmus MC, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 39:S103-12. 2012
    ..If more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable neuroendocrine tumours...
  13. ncbi request reprint Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    J P Esser
    Department of Nuclear Medicine, Erasmus MC Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 33:1346-51. 2006
    ..We compared in seven patients [(177)Lu-DOTA(0),Tyr(3)]octreotide ((177)Lu-DOTATOC) and [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-DOTATATE), to see which peptide should be preferred for PRRT with (177)Lu...
  14. ncbi request reprint Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours
    M de Visser
    Department of Nuclear Medicine, Erasmus MC, 3015 GD Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 34:1228-38. 2007
    ..However, the receptor affinity as well as the serum stability of this analogue leave room for improvement. Therefore new (111)In-labelled BN analogues were synthesised and evaluated in vitro and in vivo...
  15. ncbi request reprint Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy
    M Melis
    Department of Nuclear Medicine, Erasmus MC Rotterdam Rotterdam, The Netherlands
    Q J Nucl Med Mol Imaging 51:324-33. 2007
    ....
  16. ncbi request reprint Radiolabelled regulatory peptides for imaging and therapy
    W A P Breeman
    Erasmus MC Rotterdam, University Medical Center Rotterdam, Department of Nuclear Medicine, Dr Molewaterplein 40, Rotterdam, The Netherlands
    Anticancer Agents Med Chem 7:345-57. 2007
    ..New analogues, chelators, radionuclides and combinations thereof are discussed...
  17. doi request reprint Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus MC Rotterdam s 3015 CE Rotterdam, The Netherlands
    Nucl Med Biol 35:839-49. 2008
    ..In patient blood, the rank of radiopeptide in vivo stability was: (99m)Tc-Demogastrin 2 (t(1/2) 10-15 min)>(111)In-DOTA-CCK (t(1/2) approximately 5-10 min)>(111)In-DOTA-MG11 (t(1/2)<5 min)...
  18. ncbi request reprint 111In-octreotide scintigraphy in oncology
    E P Krenning
    Department of Nuclear Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Digestion 54:84-7. 1993
    ..abstract truncated at 250 words)..
  19. ncbi request reprint Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate
    W H Bakker
    Department of Nuclear Medicine, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Q J Nucl Med Mol Imaging 50:265-71. 2006
    ....
  20. pmc Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate
    D J Kwekkeboom
    Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 30:417-22. 2003
    ..However, in view of the high success rate of therapy with (177)Lu-octreotate and the absence of serious side-effects, we advocate its use in patients with GEP tumours without waiting for tumour progression...
  21. ncbi request reprint Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors
    E P Krenning
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Endocrinol Invest 28:146-50. 2005
    ..Also, the development of therapy strategies with combinations of different radionuclides and or peptides is of interest as these strategies may provide an increase in therapeutic efficacy in the future...
  22. pmc Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts
    Rogier P J Schroeder
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 38:1257-66. 2011
    ..We compared GRPR-based targeting using the (68)Ga-labelled bombesin analogue AMBA with metabolism-based targeting using (18)F-methylcholine ((18)F-FCH) in nude mice bearing human prostate VCaP xenografts...
  23. ncbi request reprint Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer
    M de Visser
    Department of Nuclear Medicine, Erasmus MC, 3015 GD, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 30:1134-9. 2003
    ....
  24. ncbi request reprint Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer
    L M Haslinghuis
    Department of Nuclear Medicine, University Hospital Rotterdam, The Netherlands
    J Endocrinol Invest 24:415-22. 2001
    ....
  25. doi request reprint Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues
    R P J Schroeder
    Department of Nuclear Medicine, ErasmusMC, Rotterdam, The Netherlands
    Methods 48:200-4. 2009
    ....
  26. ncbi request reprint Tc-99m sestamibi before and during treatment in a patient with sarcoidosis and persistent hyperparathyroidism
    A C Fröberg
    Department of Nuclear Medicine, University Hospital Rotterdam, The Netherlands
    Clin Nucl Med 25:351-3. 2000
    ..Tc-99m sestamibi (MIBI) uptake in pulmonary sarcoidosis has been reported, but it has never been studied before and during treatment with glucocorticoids...
  27. ncbi request reprint In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals
    F Forrer
    Department of Nuclear Medicine, Erasmus MC Rotterdam, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 33:1214-7. 2006
    ..In vivo quantification of radiopharmaceuticals has great potential as a tool in developing new drugs. We investigated the accuracy of in vivo quantification with multi-pinhole single-photon emission computed tomography (SPECT) in rats...
  28. ncbi request reprint Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability
    G Hennemann
    Department of Nuclear Medicine, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands
    Endocr Rev 22:451-76. 2001
    ..Future research should be directed to elucidate which of these and possible other transporters are of physiological significance, and how they are regulated at the molecular level...
  29. ncbi request reprint Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas
    W W de Herder
    Department of Internal Medicine Section of Endocrinology, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Endocr Relat Cancer 11:19-34. 2004
    ..The delicate balance of the use of the different therapeutical options in patients with endocrine tumours of the gastrointestinal tract and pancreas emphasizes the importance of team approach and team expertise...
  30. ncbi request reprint Validation of somatostatin receptor scintigraphy in the localization of neuroendocrine tumors
    S W Lamberts
    Department of Medicine, Erasmus University, Rotterdam, The Netherlands
    Acta Oncol 32:167-70. 1993
    ..This scintigraphic method might help in patient selection for clinical trials with somatostatin analogs in the treatment of neuroendocrine cancers...
  31. ncbi request reprint Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats
    E J Rolleman
    Department Nuclear Medicine, Room L244, Erasmus MC s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
    Nuklearmedizin 47:110-5. 2008
    ....
  32. pmc Is it possible to predict renal function in small animals using a multi-pinhole SPECT system
    F Forrer
    Eur J Nucl Med Mol Imaging 34:1127-8. 2007
  33. ncbi request reprint Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography
    C Verhoef
    Department of Surgery, University Hospital Dijkzigt, Rotterdam, The Netherlands
    Liver 22:51-6. 2002
    ....
  34. ncbi request reprint The role of octreotide scintigraphy in rheumatoid arthritis and sarcoidosis
    V A S H Dalm
    Department of Internal Medicine, Erasmus MC, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Q J Nucl Med 47:270-8. 2003
    ..In this paper we discuss the (possible) role of somatostatin receptor scintigraphy in diagnosis, staging or follow-up of patients suffering from sarcoidosis and rheumatoid arthritis...
  35. ncbi request reprint Neuroendocrine tumors and somatostatin: imaging techniques
    W W de Herder
    Section of Endocrinology, Department of Internal Medicine, Erasmus Rotterdam, The Netherlands
    J Endocrinol Invest 28:132-6. 2005
    ..A large variety of lesions in and around the pituitary region express somatostatin receptors and, therefore, can be visualized by 111In-pentetreotide scintigraphy...
  36. ncbi request reprint Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)
    U Plockinger
    Department of Hepatology and Gastroenterology, Interdisciplinary Center for Metabolism, Endocrinology, and Diabetes, Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
    Neuroendocrinology 80:394-424. 2004
  37. ncbi request reprint Tissue distribution of octreotide binding receptors in normal mice and strains prone to autoimmunity
    A M C Ten Bokum
    Department of Immunology, Erasmus Medical Centre Rotterdam, Dr Molewaterplein 40, 3015 GD Rotterdam, Netherlands
    Nucl Med Commun 23:1009-17. 2002
    ..To our knowledge, this is the first report on the tissue distribution of octreotide binding receptors in mice...